Loading
Latest filing published 22 Sept 2026 for Hikma Pharmaceuticals PLC, €3,855.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Sam Park is a declared insider of Hikma Pharmaceuticals PLC, with filings sourced from RNS (LSE). In total, 3 filings cover trades dated from 7 April 2026 to 21 September 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 22 September 2026 came the latest disclosure, a share grant for €3,855 in Hikma Pharmaceuticals PLC. The median gap between a trade and its publication by RNS (LSE) is 2 days. For comparison, UK MAR gives managers three business days to notify a trade. Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations